¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"receptor destroying enzyme"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
À̰ÍÀ» ¿øÇϼ̽À´Ï±î?
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • extracellular enzyme
    ¼¼Æ÷¿ÜÈ¿¼Ò
  • enzyme
    È¿¼Ò
  • enzyme activity
    È¿¼ÒȰ¼º, È¿¼ÒȰ¼ºµµ
  • enzyme assay
    È¿¼ÒÃøÁ¤
  • enzyme immunoassay
    È¿¼Ò¸é¿ªºÐ¼®(¹ý)
  • enzyme inhibition
    È¿¼Ò¾ïÁ¦
  • enzyme inhibitor
    È¿¼Ò¾ïÁ¦Á¦
  • enzyme labeled antibody
    È¿¼ÒÇ¥ÁöÇ×ü
  • enzyme labeling
    È¿¼ÒÇ¥Áö
  • enzyme modulator mediated immunoassay
    È¿¼ÒÁ¶Àý¸Å°³¸é¿ªºÐ¼®(¹ý)
  • enzyme precursor
    È¿¼ÒÀü±¸¹°Áú
  • enzyme-antibody conjugate
    È¿¼ÒÇ×üÁ¢ÇÕü
  • enzyme-antienzyme reaction
    È¿¼ÒÇ×È¿¼Ò¹ÝÀÀ
  • enzyme-linked immunoelectrotransfer blot
    È¿¼Ò°áÇո鿪ÀÌÀû¹ý, È¿¼Ò¿¬°ü¸é¿ªÀü±âÀü´Þ¹ý
  • enzyme-linked immunosorbent assay
    È¿¼Ò°áÇո鿪ÈíÂøÃøÁ¤(¹ý)
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 3 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • regulatory enzyme
    Á¶ÀýÈ¿¼Ò
  • respiratory enzyme
    È£ÈíÈ¿¼Ò
  • restriction enzyme
    Á¦ÇÑÈ¿¼Ò
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • curdling enzyme
    ÀÀÀ¯È¿¼Ò
  • cytosolic enzyme
    ¼¼Æ÷ÁúÈ¿¼Ò
  • enzyme-antibody conjugate
    È¿¼ÒÇ×üÁ¢ÇÕü
  • debrancher enzyme
    °¡ÁöÁ¦°ÅÈ¿¼Ò
  • degumming enzyme
    ÇØ±³È¿¼Ò
  • diastatic enzyme
    ´çÈ­È¿¼Ò
  • digestive enzyme
    ¼ÒÈ­È¿¼Ò
  • enzyme
    È¿¼Ò
  • enzyme immunoassay
    È¿¼Ò¸é¿ªºÐ¼®(¹ý)
  • enzyme inhibition
    È¿¼Ò¾ïÁ¦
  • enzyme inhibitor
    È¿¼Ò¾ïÁ¦Á¦
  • enzyme labeling
    È¿¼ÒÇ¥Áö
  • enzyme precursor
    È¿¼ÒÀü±¸Ã¼
  • enzyme modulator mediated immunoassay
    È¿¼ÒÁ¶Àý¸Å°³¸é¿ªºÐ¼®(¹ý)
  • enzyme trace substance theory
    È¿¼ÒÈçÀû¹°¼³
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • heterogeneous enzyme immunoassay
    ºÒ±ÕÀÏ<--Áú>È¿¼Ò¸é¿ªÇÐÀûÃøÁ¤(¹ý)
  • homogeneous enzyme immunoassay
    ±ÕÁúÈ¿¼Ò¸é¿ªÃøÁ¤(¹ý)
  • induced enzyme
    À¯µµÈ¿¼Ò.
  • inducible enzyme
    À¯µµ(¹ß)È¿¼Ò.
  • inducible enzyme
    À¯¹ß°¡´ÉÈ¿¼Ò
  • inhibitory enzyme
    ÀúÇØÈ¿¼Ò.
  • inorganic enzyme
    ¹«±âÈ¿¼Ò(ÙíѦý£áÈ).
  • phosphorylating enzyme
    ÀλêÈ­È¿¼Ò(ìÝß« ûùý£áÈ).
  • prosthetic group-labeled enzyme
    º¸Á¶±ºÇ¥ÁöÈ¿¼Ò
  • rate limiting enzyme
    ¼ÓµµÁ¶ÀýÈ¿¼Ò(áÜöôðàï½ý£áÈ).
  • redox enzyme
    »êȭȯ¿øÈ¿¼Ò(ß«ûùü»êªý£áÈ).
  • reducing enzyme
    ȯ¿øÈ¿¼Ò(ü½êªý£áÈ).
  • regulatory enzyme
    Á¶ÀýÈ¿¼Ò(¡­ý£áÈ).
  • A1 receptor
    A1 ¼ö¿ëü(¼ö¿ë±â, °¨¼ö±â)
  • A2 receptor
    A2 ¼ö¿ëü(¼ö¿ë±â, °¨¼ö±â)
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • brancher enzyme deficiency
    ºÐÁöÈ¿¼Ò°áÇÌ(Áõ)
  • brancher enzyme deficiency
    ºÐÁöÈ¿¼Ò°áÇÌ(¡­ý£áÈÌÀù¹).
  • branching enzyme
    °¡ÁöÄ¡±âÈ¿¼Ò, ºÐÁöÈ¿¼Ò.
  • catheptic enzyme
    Ä«µª½ÅÈ¿¼Ò(¡­ý£áÈ).
  • constitutive enzyme
    ±¸¼ºÈ¿¼Ò(ϰà÷ý£áÈ).
  • constitutive enzyme
    ±¸¼ºÀûÈ¿¼Ò (±âº»)
  • converting enzyme inhibitor
    Àüȯȿ¼Ò¾ïÁ¦Á¦.
  • covalently modulated enzyme
    °øÀ¯°áÇÕ¸ðµâÈ­È¿¼Ò.
  • cuprein enzyme
    Å¥ÇÁ·¹ÀÎÈ¿¼Ò
  • curdling enzyme
    ÀÀÀ¯È¿¼Ò(¡­ý£áÈ).
  • cytosolic enzyme
    ¼¼Æ÷ÁúÈ¿¼Ò.
  • debrancher enzyme
    ÁöÁ¦°ÅÈ¿¼Ò(ò«ð¶ËÛý£áÈ)
  • degumming enzyme
    ÇØ±³È¿¼Ò(ú°Îïý£áÈ).
  • diastatic enzyme
    ´çÈ­È¿¼Ò(ÓØûùý£áÈ).
  • digestive enzyme
    ¼ÒÈ­È¿¼Ò(á¼ûùý£áÈ).
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • mineralocorticoid receptor
    ±¤Áú(ÎÎòõ) ÄÚ¸£Æ¼ÄÚÀÌµå ¼ö¿ëü(áôé»ô÷)
  • mobile receptor model
    À̵¿¼ö¿ëü(ì¹ÔÑáôé»ô÷) ¸ðµ¨
  • muscarinic receptor
    ¹«½ºÄ«¸°¼ö¿ëü(áôéÄô÷)
  • nicotinic receptor
    ´ÏÄÚÆ¾¼ö¿ëü(â¥é»ô÷)
  • opiate receptor
    ¾ÆÆíÁ¦(ð¥) ¼ö¿ëü(áôé»ô÷)
  • opioid receptor
    ¾ÆÆí°è(ͧ) ¾à¹°¼ö¿ëü(å·Úªáôé»ô÷)
  • receptor
    ¼ö¿ëü(áôé»ô÷)
  • receptor down regulation
    ¼ö¿ëü ÇÏÇâ Á¶Àý(áôé»ô÷ù»ú¾ðàï½)
  • receptor element
    ¼ö¿ëü Á¶Àý ¿ä¼Ò(áôé»ô÷ðàï½é©áÈ)
  • receptor gradient
    ¼ö¿ëü ±¸¹è(áôé»ô÷ÎþÛÕ)
  • receptor internalization
    ¼ö¿ëü ³»ÀÔ(áôé»ô÷Ò®ìý)
  • receptor-mediated endocytosis
    ¼ö¿ëü¸Å°³ ¼¼Æ÷³» ÀÌÀÔ(áôé»ô÷ØÚË¿á¬øàÒ®ì¹ìý)
  • ribosome receptor
    ¶óÀ̺¸¼Ø ¼ö¿ëü(áôé»ô÷)
  • spare receptor
    ¿¹ºñ(çãÝá) ¼ö¿ëü (â¥é»ô÷)
  • SRP receptor
    SRP ¼ö¿ëü(áôé»ô÷)
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
RAR rapidly adapting receptor; rat insulin receptor; retinoic acid receptor; right arm reclining; right ...
HRE hepatic reticuloendothelial [cell]; high-resolution electrocardiography; hormone receptor enzyme
CR calculation rate; calculus removed; calorie-restricted; cardiac rehabilitation; cardiac resuscitatio...
CRL cell repository line; Certified Record Librarian; complement receptor location; complement receptor ...
DR degeneration reaction; delivery room; deoxyribose; diabetic retinopathy; diagnostic radiology; digit...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
ACEi Angiotensin I converting enzyme inhibition
ACE Angiotensin converting enzyme activity
ACE inhibitor angiotensin converting enzyme inhibitor
ADEPT Antibody Directed Enzyme Prodrug Therapy
AOE anti-oxidant enzyme
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • heterogeneous enzyme immunoassay
    ºÒ±ÕÀÏ È¿¼Ò ¸é¿ªÇÐÀû ÃøÁ¤, ºÒ±ÕÀÏ È¿¼Ò ¸é¿ªÇÐÀû ÃøÁ¤¹ý
  • induced enzyme
    À¯µµ È¿¼Ò
    ±âÁú ¶Ç´Â ±×¿Í ±¸Á¶ÀûÀ¸·Î ¿¬°üµÈ, À¯µµ ¹°ÁúÀÇ Àڱؿ¡ ÀÇÇÏ¿© »ý¼ºµÈ È¿¼Ò.
  • lipolytic enzyme
    Áö¹æ ºÐÇØ È¿¼Ò
  • lysosomal enzyme
    ¸®¼ÒÁ» È¿¼Ò, ¿ëÇØ ¼Òü È¿¼Ò
  • microsomal enzyme
    ¹Ì¼Òü È¿¼Ò
  • microsomal enzyme system
    ¹Ì¼Òü È¿¼Ò°è
  • neural enzyme system
    ½Å°æ È¿¼Ò°è
  • pancreatic enzyme
    Ãé È¿¼Ò
    ÃéÀå¿¡¼­ ºÐºñµÇ´Â ź¼öÈ­¹°, Áö¹æ, ´Ü¹éÁúÀ» ºÐÇØÇÏ´Â È¿¼Ò.
  • periplasmic enzyme
    ¿øÇüÁú¸· ÁÖÀ§ °ø°£ È¿¼Ò
  • phosphorylating enzyme
    ÀλêÈ­ È¿¼Ò
  • proteolytic enzyme
    ´Ü¹é ºÐÇØ È¿¼Ò
    ´Ü¹é ºÐÇØ¸¦ ÃËÁøÇÏ´Â È¿¼Ò.
  • Q enzyme
    Å¥ È¿¼Ò
    Æ÷µµ´ç-1-ÀλêÀÇ 1,6-C¿¡ ÀÛ¿ëÇÏ¿© À̰ÍÀ» ÁßÈ­½ÃŰ´Â È¿¼Ò.
  • rate-limiting enzyme
    ¼Óµµ Á¶Àý È¿¼Ò
  • splitting enzyme
    ºÐÇÒ È¿¼Ò
  • Z-enzyme
    ÁîÀÌ È¿¼Ò
    º£Å¸-¾Æ¹Ð¶óÁ¦¿Í Çù·ÂÇÏ¿© ¾Æ¹Ð·ÎÁ¦ÀÇ ¿ÏÀü ºÐÇØ¸¦ ÀÏÀ¸Å²´Ù.
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
gene rearrangement, delta-chain T-cell antigen receptor Ordered rearrangement of T-cell variable gene regions coding for the delta-chain of antigen receptors.
(12 Dec 1998)
gene rearrangement, gamma-chain T-cell antigen receptor Ordered rearrangement of T-cell variable gene regions coding for the gamma-chain of antigen receptors.
(12 Dec 1998)
genes, T-cell receptor DNA sequences, in cells of the t-lymphocyte lineage, that code for T-cell receptors. The tcr genes are formed by somatic rearrangement (see gene rearrangement, t-lymphocyte and its children) of germline gene segments, and resemble ig genes in their mechanisms of diversity generation and expression.
(12 Dec 1998)
genes, T-cell receptor alpha DNA sequences encoding the alpha chain of the T-cell receptor. The genomic organization of the tcr alpha genes is essentially the same in all species and is similar to the organization of ig genes.
(12 Dec 1998)
genes, T-cell receptor beta DNA sequences encoding the beta chain of the T-cell receptor. The genomic organization of the tcr beta genes is essentially the same in all species and is similar to the organization of ig genes.
(12 Dec 1998)
genes, T-cell receptor delta DNA sequences encoding the delta chain of the T-cell receptor. The delta-chain locus is located entirely within the alpha-chain locus.
(12 Dec 1998)
genes, T-cell receptor gamma DNA sequences encoding the gamma chain of the T-cell receptor. The human gamma-chain locus is organised similarly to the tcr beta-chain locus.
(12 Dec 1998)
receptor 1. A molecular structure within a cell or on the surface characterised by selective binding of a specific substance and a specific physiologic effect that accompanies the binding, for example, cell surface receptors for peptide hormones, neurotransmitters, antigens, complement fragments and immunoglobulins and cytoplasmic receptors for steroid hormones.
2. A sensory nerve terminal that responds to stimuli of various kinds.
(18 Nov 1997)
receptor aggregation Chemically stimulated aggregation of cell surface receptors, which potentiates the action of the effector cell.
(12 Dec 1998)
receptor agonist A substance that mimics a specificneurotransmitter, is able to attach to that neurotransmitter's receptor and thereby produces the same action that theneurotransmitter usually produces. Drugs are often designed as receptor agonists to treat a variety of diseases and disorders whenthe original chemical substance is missing or depleted.
(22 May 1997)
receptor-CD3 complex, antigen, T-cell Molecule composed of the non-covalent association of the T-cell antigen receptor (receptors, antigen, T-cell) with the CD3 complex (antigens, CD3). This association is required for the surface expression and function of both components. The molecule consists of up to seven chains: either the alpha/beta or gamma/delta chains of the T-cell receptor, and four or five chains in the CD3 complex.
(12 Dec 1998)
receptor, chemokine A molecule that receives a chemokine and acts as a dock for a chemokine. Several chemokine receptors are essential co-receptors for HIV.
(12 Dec 1998)
receptor downregulation A phenomenon observed in many cells: following stimulation with a ligand the number of receptors for that ligand on the cell surface diminishes because internalisation exceeds replenishment. Often used very loosely, thus destroying the utility of the term.
(18 Nov 1997)
receptor mediated endocytosis Endocytosis of molecules by means of a specific receptor protein that normally resides in a coated pit, but may enter this structure after complex formation occurs. The structure then forms a coated vesicle that delivers its contents to the endosome whence it may enter the cytoplasm or the lysosomal compartment. Many bacterial toxins and viruses enter cells by this route.
(18 Nov 1997)
receptor potential The transmembrane potential difference of a sensory cell. Such cells are not generally excitable, but their response to stimulation is a gradual change in their resting potential.
(18 Nov 1997)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
ÅëÇÕ°Ë»ö ¿Ï·á